Literature DB >> 27589969

Quantitative Information on Oncology Prescription Drug Websites.

Helen W Sullivan1, Kathryn J Aikin2, Linda B Squiers3.   

Abstract

Our objective was to determine whether and how quantitative information about drug benefits and risks is presented to consumers and healthcare professionals on cancer-related prescription drug websites. We analyzed the content of 65 active cancer-related prescription drug websites. We assessed the inclusion and presentation of quantitative information for two audiences (consumers and healthcare professionals) and two types of information (drug benefits and risks). Websites were equally likely to present quantitative information for benefits (96.9 %) and risks (95.4 %). However, the amount of the information differed significantly: Both consumer-directed and healthcare-professional-directed webpages were more likely to have quantitative information for every benefit (consumer 38.5 %; healthcare professional 86.1 %) compared with every risk (consumer 3.1 %; healthcare professional 6.2 %). The numeric and graphic presentations also differed by audience and information type. Consumers have access to quantitative information about oncology drugs and, in particular, about the benefits of these drugs. Research has shown that using quantitative information to communicate treatment benefits and risks can increase patients' and physicians' understanding and can aid in treatment decision-making, although some numeric and graphic formats are more useful than others.

Entities:  

Keywords:  Cancer; Internet; Marketing; Prescription drug

Mesh:

Substances:

Year:  2018        PMID: 27589969      PMCID: PMC5334459          DOI: 10.1007/s13187-016-1107-1

Source DB:  PubMed          Journal:  J Cancer Educ        ISSN: 0885-8195            Impact factor:   2.037


  13 in total

Review 1.  A meta-analysis of the effects of presenting treatment benefits in different formats.

Authors:  Judith Covey
Journal:  Med Decis Making       Date:  2007-09-14       Impact factor: 2.583

Review 2.  Cancer-related direct-to-consumer advertising: a critical review.

Authors:  Emily Z Kontos; K Viswanath
Journal:  Nat Rev Cancer       Date:  2011-02       Impact factor: 60.716

3.  Update on Direct-to-Consumer Marketing in Oncology.

Authors:  Stacy W Gray; Gregory A Abel
Journal:  J Oncol Pract       Date:  2012-02-21       Impact factor: 3.840

Review 4.  Communicating quantitative risks and benefits in promotional prescription drug labeling or print advertising.

Authors:  Suzanne L West; Linda B Squiers; Lauren McCormack; Brian G Southwell; Emily S Brouwer; Mahima Ashok; Linda Lux; Vanessa Boudewyns; Amie O'Donoghue; Helen W Sullivan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-02-26       Impact factor: 2.890

Review 5.  Evidence-based risk communication: a systematic review.

Authors:  Daniella A Zipkin; Craig A Umscheid; Nancy L Keating; Elizabeth Allen; KoKo Aung; Rebecca Beyth; Scott Kaatz; Devin M Mann; Jeremy B Sussman; Deborah Korenstein; Connie Schardt; Avishek Nagi; Richard Sloane; David A Feldstein
Journal:  Ann Intern Med       Date:  2014-08-19       Impact factor: 25.391

6.  Direct-to-consumer advertising in oncology: a content analysis of print media.

Authors:  Gregory A Abel; Stephanie J Lee; Jane C Weeks
Journal:  J Clin Oncol       Date:  2007-04-01       Impact factor: 44.544

7.  The attitudes and beliefs of oncology nurse practitioners regarding direct-to-consumer advertising of prescription medications.

Authors:  Pamela Hallquist Viale; Deanna Sanchez Yamamoto
Journal:  Oncol Nurs Forum       Date:  2004-07-13       Impact factor: 2.172

8.  Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment.

Authors:  Gregory A Abel; Harold J Burstein; Nathanael D Hevelone; Jane C Weeks
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

9.  Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing.

Authors:  Deborah Korenstein; Salomeh Keyhani; Ali Mendelson; Joseph S Ross
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

10.  Content analysis of oncology-related pharmaceutical advertising in a peer-reviewed medical journal.

Authors:  Kan Yonemori; Akihiro Hirakawa; Masashi Ando; Taizo Hirata; Mayu Yunokawa; Chikako Shimizu; Kenji Tamura; Yasuhiro Fujiwara
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more
  2 in total

1.  Disclosing accelerated approval on direct-to-consumer prescription drug websites.

Authors:  Helen W Sullivan; Amie C O'Donoghue; Kathleen T David; Nisha J Patel
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-09-28       Impact factor: 2.890

2.  Cancer treatment in the last 6 months of life: when inaction can outperform action.

Authors:  Bishal Gyawali; Saroj Niraula
Journal:  Ecancermedicalscience       Date:  2018-04-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.